神经保护市场:现状分析与预测(2022-2030年)

由于神经系统疾病患病率不断上升，神经保护市场预计将以6%左右的速度稳定增长。由于衰老、遗传倾向和生活方式等因素，阿尔茨海默病、帕金森病和多发性硬化症等神经系统疾病的发病率正在增加。

根据产品类型，市场分为自由基清除剂（抗氧化剂）、细胞凋亡抑製剂、抗炎剂、谷氨酸拮抗剂（抗刺激毒物）等。由于人口老龄化和阿尔茨海默氏症和帕金森氏症等神经退行性疾??病患病率的上升，自由基清除剂（抗氧化剂）类别在预测期内将表现出较高的复合年增长率，进一步推动该细分市场的增长。

根据应用，它分为神经退行性疾??病、阿尔茨海默病、帕金森病、多发性硬化症等。其中，神经退行性疾??病将在2021年占据很大的市场占有率。这主要是由于神经退行性疾??病的患病率不断增加，人们越来越意识到维持大脑健康的重要性，以及对有效治疗的需求推动了神经保护市场的增长。例如，根据国际癌症研究机构的数据，全球大多数研究表明每年每 10 万人中有 10 至 15 例癌症发病。65岁以上人群的患病率可达2%。调查对象被各终端用户，医院·专门诊所，研究机关·学术中心，看护设施，其他分类。在预测期间内，一般认为医院·专门诊所的类别神经保护的招聘增加。这为了主要，受到比神经疾病的正确的诊断因为是希望住院的患者多的事，神经疾病的盛行率的增加，个人化医疗的需求高涨等，促进神经科学市场上医疗保健供应商领域的成长。

按最终用户划分，调查对象分为医院/专科诊所、研究机构/学术中心、疗养院等。在预测期内，医院和专科诊所类别的神经保护采用预计将会增加。这主要是由于越来越多的患者寻求住院接受更准确的神经系统疾病诊断、神经系统疾病的患病率不断增加以及个性化医疗的需求不断增长，从而推动了医疗服务提供商领域的增长。

为了更好地了解神经保护行业的市场采用情况，市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、意大利、欧洲其他地区）、亚太地区（中国、日本、印度、亚太地区其他地区）、世界其他地区根据其在世界其他地区的存在情况进行分析。北美在预测期内预计将以显着的复合年增长率增长，因为它拥有大量老年人口并构成美国社会的很大一部分。根据社区生活管理局的数据，2019 年美国老年人数量自 2009 年以来增加了 1440 万（即 36%）。随着年龄的增长，神经系统疾病的风险也随之增加，这将是神经保护市场增长以应对不断增加的病例的关键因素。此外，该地区和美国等主要经济体先进技术的存在也有助于北美神经保护行业的重要市场占有率。

目录

第1章 市场简介

• 市场定义
• 主要目的
• 相关利益者
• 限制事项

第2章 调查手法或前提

• 调查流程
• 调查手法
• 受访者简介

第3章 市场摘要

第4章 摘要整理

第5章 COVID-19对神经保护市场带来的影响

第6章 神经保护市场收益，2020-2030年

第7章 市场洞察:各产品类型

• 自由基理解剂(抗氧化剂)
• 细胞凋亡抑制剂
• 抗发炎剂
• 麸胺酸拮抗剂(抗兴奋毒性剂)
• 其他

第8章 市场洞察:各用途

• 神经退化性疾病
• 阿兹海默症
• 帕金森氏症
• 多发性硬化症
• 其他

第9章 市场洞察:各终端用户

• 医院和专门诊所
• 调查机关和学术中心
• 看护设施
• 其他

第10章 市场洞察:各地区

• 北美
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 全球其他地区

第11章 神经保护市场动态

• 推动市场要素
• 市场课题
• 影响分析

第12章 神经保护市场机会

第13章 神经保护市场趋势

第14章 需求面和供给面的分析

• 需求面分析
• 供给面分析

第15章 价值链分析

第16章 价格分析

第17章 策略性洞察能力

第18章 竞争模式

• 竞争情形
  • 波特的五力分析

第19章 企业简介

• AbbVie Inc.
• DAIICHI SANKYO COMPANY
• Astrocyte Pharmaceuticals
• AstraZeneca
• Biogen
• Novartis AG
• Lilly
• F. Hoffmann-La Roche Ltd
• Teva Pharmaceutical Industries Ltd.
• Merck KGaA

第20章 免责声明

Neuroprotection refers to the process of protecting the nervous system from damage or degeneration. The nervous system is a complex network of cells and tissues that controls the body's functions, including movement, sensation, and cognition. Neuroprotection can be achieved through various means, including the use of drugs, therapies, and lifestyle modifications. For example, drugs that target specific proteins or enzymes involved in the process of neurodegeneration can be used to protect the nervous system. Therapies such as physical therapy, occupational therapy, and speech therapy can also be used to protect the nervous system by promoting nerve function and preventing further damage.

The neuroprotection market is expected to grow at a steady rate of around 6% owing to the Increasing prevalence of neurological disorders. The incidence of neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis is increasing due to factors such as an aging population, genetic predisposition, and lifestyle factors. For instance, as per WHO, more than 55 million people were diagnosed with dementia in 2021, and there are nearly 10 million new cases every year. Also, in 2019, globally, 50 million people were diagnosed with epilepsy.

Based on product type, the market is segmented into free radical trapping agents (antioxidants); apoptosis inhibitors; anti-inflammatory agents; glutamate antagonists (anti-excitotoxic agents); and others. The free radical trapping agents (antioxidants) category to witness higher CAGR during the forecast period owing to the aging population and the rising incidence of neurodegenerative diseases such as Alzheimer's and Parkinson's are driving the demand for neuroprotection treatments which will further boost the growth of this segment.

On the basis of application, the market is categorized into neurodegenerative disorders, alzheimer's disease, parkinson's disease, multiple sclerosis, and other. Among these, the neurodegenerative disorders held a significant share in the market in 2021. This is mainly due to the increasing prevalence of neurodegenerative disorders, the growing awareness of the importance of maintaining brain health, and the need for effective treatments are driving the growth of the neuroprotection market. For instance, as per International Agency for Research on Cancer, annual incidence rates of 10-15 per 100 000 have been noted in most surveys worldwide. Prevalence may reach 2% in persons aged 65 years and older

Based on end-user, the neuroprotection market has been classified into hospitals & specialty clinics, research institutes & academic centers, long-term care facilities, and others. The hospitals & specialty clinics category is to witness higher adoption of neuroprotection during the forecast period. This is mainly due to the high preference of patients for hospitalization to have a more accurate diagnosis of their neurological diseases, increasing prevalence of neurological disorders, coupled with the rising demand for personalized medicine, is driving the growth of the healthcare provider segment in the neuroscience market.

For a better understanding of the market adoption of the neuroprotection industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. owing to the North America is home to a large geriatric population and consists of a significant portion of American society. As per the administration for community living, the number of older Americans has increased by 14.4 million (or 36%) since 2009 in 2019. With the rising age, the risk of neurological disorders also increases which becomes an important factor for the growth of the neuroprotection market to deal with the increasing cases. Furthermore, the presence of advanced technology in the region and the major economies such as the U.S. is also a responsible factor for the large market share of neuroprotection industry in North America.

Some of the major players operating in the market include: AbbVie Inc.; DAIICHI SANKYO COMPANY; Astrocyte Pharmaceuticals; AstraZeneca; Biogen; Novartis AG; Lilly; F. Hoffmann-La Roche Ltd; Teva Pharmaceutical Industries Ltd.; and Merck KGaA.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Neuroprotection Market
• 2.2. Research Methodology of the Neuroprotection Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE NEUROPROTECTION MARKET

6 NEUROPROTECTION MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY PRODUCT TYPE

• 7.1. Free Radical Trapping Agents (Antioxidants)
• 7.2. Apoptosis Inhibitors
• 7.3. Anti-inflammatory Agents
• 7.4. Glutamate Antagonists (Anti-Excitotoxic Agents)
• 7.5. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Neurodegenerative Disorders
• 8.2. Alzheimer's Disease
• 8.3. Parkinson's Disease
• 8.4. Multiple Sclerosis
• 8.5. Other

9 MARKET INSIGHTS BY END-USER

• 9.1. Hospitals & Specialty Clinics
• 9.2. Research Institutes & Academic Centers
• 9.3. Long-Term Care Facilities
• 9.4. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 NEUROPROTECTION MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 NEUROPROTECTION MARKET OPPORTUNITIES

13 NEUROPROTECTION MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

• 18.1. Competitive Landscape
  • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

• 19.1. AbbVie Inc.
• 19.2. DAIICHI SANKYO COMPANY
• 19.3. Astrocyte Pharmaceuticals
• 19.4. AstraZeneca
• 19.5. Biogen
• 19.6. Novartis AG
• 19.7. Lilly
• 19.8. F. Hoffmann-La Roche Ltd
• 19.9. Teva Pharmaceutical Industries Ltd.
• 19.10. Merck KGaA

20 DISCLAIMER